Compass Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
Condensed Consolidated Statements of Stockholders**’** Equity**
(In thousands)
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at December 31, 2023 | 127,668 | $13 | $463,796 | $37 | $(315,308) | $148,538 |
| Common shares issued, net of issuance costs of $0.5 million | 9,790 | 1 | 17,568 | — | — | 17,569 |
| Share-based awards, net of tax remittance | 131 | (136) | — | — | (136) | |
| Stock-based compensation | — | — | 2,003 | — | — | 2,003 |
| Unrealized loss on marketable securities | — | — | — | (127) | — | (127) |
| Net loss | — | — | — | — | (10,787) | (10,787) |
| Balance at March 31, 2024 | 137,589 | 14 | 483,231 | (90) | (326,095) | 157,060 |
| Stock-based compensation | — | — | 2,121 | — | — | 2,121 |
| Unrealized loss on marketable securities | — | — | — | (1) | — | (1) |
| Net loss | — | — | — | — | (13,076) | (13,076) |
| Balance at June 30, 2024 | 137,589 | $14 | $485,352 | $(91) | $(339,171) | $146,104 |
| Balance at December 31, 2022 | 126,302 | $13 | $454,741 | $(302) | $(272,814) | $181,638 |
| Vesting of share-based awards | 61 | — | — | — | — | — |
| Stock-based compensation | — | — | 1,267 | — | — | 1,267 |
| Common stock issued upon exercise of options | 12 | — | 41 | — | — | 41 |
| Unrealized gain on marketable securities | — | — | — | 156 | — | 156 |
| Net loss | — | — | — | — | (7,837) | (7,837) |
| Balance at March 31, 2023 | 126,375 | 13 | 456,049 | (146) | (280,651) | 175,265 |
| Common shares issued, net of issuance costs of $0.1 million | 952 | — | 3,032 | — | — | 3,032 |
| Vesting of share-based awards | 61 | — | — | — | — | — |
| Stock-based compensation | — | — | 1,628 | — | — | 1,628 |
| Unrealized loss on marketable securities | — | — | — | (361) | — | (361) |
| Net loss | — | — | — | — | (11,278) | (11,278) |
| Balance at June 30, 2023 | 127,388 | $13 | $460,709 | $(507) | $(291,929) | $168,286 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.